

The Role of Medication in Substance Use Treatment

References – Part 2

Detoxification

1. American Psychiatric Association. Practice Guidelines for Treatment of Patients with Substance Use Disorders: Alcohol, Cocaine, Opioids. Washington, DC: American Psychiatric Association. 1995.

Should Referral for Detoxification be Considered?

1. Center for Substance Abuse Treatment. Detoxification and Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 45. DHHS Publication No. (SMA) 06-4131. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.
2. American Psychiatric Association. *Practice Guidelines for Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine, Opioids*. Washington, DC: American Psychiatric Association. 1995.

Alcohol Dependence - Disulfiram (Antabuse) - 1

1. Banys P. The clinical use of disulfiram (Antabuse): a review. *J Psychoactive Drugs*. 1988;20:243–61.

Alcohol Dependence - Disulfiram (Antabuse) - 2

1. Banys P. The clinical use of disulfiram (Antabuse): a review. *J Psychoactive Drugs*. 1988;20:243–61.
2. Kranzler HR, Ciraulo DA. Clinical Manual of Addiction Psychopharmacology. American Psychiatric Publishing, Washington, DC. 2005.

Alcohol Dependence - Disulfiram (Antabuse) - 3

1. Peachey JE, Naranjo CA. The use of disulfiram and other alcohol sensitizing drugs in the treatment of alcoholism. *Res Adv Alcohol Drug Probl*. 1983;7:397-431.
2. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. *JAMA*. 1999;281:1318-25.
3. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. *JAMA*. 1986;256:1449–55.
4. Allen JP, Litten RZ. Techniques to enhance compliance with disulfiram. *Alcohol Clin Exp Res*. 1992;16:1035–41.
5. Roozen HG, Boulogne JJ, van Tulder MW, et al. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. *Drug Alcohol Depend*. 2004;74:1–13.
6. Hughes JC, Cook CCH. The efficacy of disulfiram: a review of outcome studies. *Addiction*. 1997;92:381–95.

The Role of Medication in Substance Use Treatment

References – Part 2

Alcohol Dependence Naltrexone (Revia) - 1

1. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol "high" in alcoholics. *Am J Psychiatry*. 1995;152:613-615.

Alcohol Dependence Naltrexone (Revia) - 2

1. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. *Alcohol Alcohol*. 2001;36:544-52.
2. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. *Alcohol Clin Exp Res*. 2001;25:1335-41.
3. Bouza C, Angeles M, Munoz A, Amate J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. *Addiction*. 2004;99:811-28.
4. Garbutt JC, West SL, Carey TS, et al. Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence. *JAMA*. 1999;281:1318-25.
5. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. *Arch Gen Psychiatry*. 1997;54:737-42.

Alcohol Dependence Acamprosate (Campral) - 1

1. Littleton J. Acamprosate in alcohol dependence: how does it work? *Addiction*. 1995;90:1179-88.
2. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. *Am J Addict*. 2003;12:S3-S11.

Alcohol Dependence Acamprosate (Campral) - 2

1. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. *Alcohol Clin Exp Res*. 2004;28:51-63.
2. Chick J, Lehert P, Landron F. Does acamprosate improve reduction of drinking as well as aiding abstinence? *J Psychopharmacol*. 2003;17:397-402.
3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. *J Clin Psychiatry*. 2001;62:42-8.
4. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. *Addiction*. 2004;99:811-28.
5. Anton RF, O'Malley SS, Ciraulo DA, et al. for the COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: A randomized controlled trial. *JAMA*. 2006;295:2003-17.

Alcohol Dependence Naltrexone Depot (Vivitrol)

1. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA*. 2005;293:1617-25.

The Role of Medication in Substance Use Treatment

References – Part 2

Opioid Dependence Methadone

1. Dole V, Robinson J, Orraca J, et al. Methadone treatment of randomly selected criminal addicts. *NEJM*. 1969;280:1372-5.
2. Yancovitz S, Des Jarlais D, Peskoe Peyser N, et al. A randomized trial of an interim methadone maintenance clinic. *Am J of Pub Health*. 1991;81:1185-91.
3. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev*. 2003;(2):CD002209.
4. Ball JC, Ross A. *The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes*. New York: Springer-Verlag; 1991.
5. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. *J Acquir Immune Defic Syndr*. 1993;6:1049-56.
6. Hubbard RL, Marsden ME, Rachal JV, et al. *Drug Abuse Treatment: A National Study of Effectiveness*. Chapel Hill, University of North Carolina Press, 1989
7. McGlothlin W, Anglin D. Shutting off methadone: costs and benefits. *Arch Gen Psychiatry*. 1981;38:885-92.

Opioid Dependence Buprenorphine (Subutex)

1. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. *Ann Intern Med*. 2000;133:40-54.

Opioid Dependence Buprenorphine (Suboxone)

1. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. *JAMA*. 1992;267:2750-5.
2. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psych*. 1996;53:401-7.
3. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. *Ann Intern Med*. 2000;133:40-54.

Opioid Dependence Naltrexone (Revia)

1. Callahan E, Rawson R, McCleave B, et al. The treatment of heroin addiction: naltrexone alone and with behavior therapy. *Int J Addict*. 1980;15:795-807.
2. Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. *Clin Pharm*. 1984;3:273-80.
3. Washton AM, Gold MS, Pottash AC. Successful use of naltrexone in addicted physicians and business executives. *Adv Alcohol Subst Abuse*. 1984;4:89-96.
4. Gold MS, Dackis CA, Pottash ALC, et al. Naltrexone, opiate addiction, and endorphins. *Med Res Rev*. 1982;2:211-46.

Stabilize Other Disorders - 1

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA*. 1990;264:2511-8.
2. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1997;54:313-21.

The Role of Medication in Substance Use Treatment

References – Part 2

Stabilize Other Disorders - 2

1. Greenfield SF, Weiss RD, Muenz LR, et al. The effect of depression on return to drinking: a prospective study. *Arch Gen Psychiatry*. 1998;55;259-65.
2. Brown PJ, Stout R, Mueller T. Post-traumatic stress disorder and substance abuse relapse among women: A pilot study. *Psychology of Addictive Behaviors*. 1996;10;124-8.
3. Driessen M, Meier S, Hill A, et al. The course of anxiety, depression, and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. *Alcohol and Alcoholism*. 2001;36;249-55.
4. Brown PJ, Stout RL. Six-month posttreatment outcomes of substance use disordered patients with and without comorbid PTSD. In P. C. Ouimette & P. J. Brown (Co-Chairs), Posttraumatic stress disorder and substance abuse: New findings. Symposium conducted at the 13th annual meeting of the International Society for Traumatic Stress Studies, Montreal. Brown and Stout. 1997.
5. Rounsaville BJ, Dolinsky ZS, Babor TF, Meyer RE. Psychopathology as a predictor of treatment outcome in alcoholics. *Arch Gen Psychiatry*. 1987;44;505-13.
6. Hasin DS, Tsai WY, Endicott J, et al. The effects of major depression on alcoholism. *Am J Addict*. 1996;5:144-55.
7. Ouimette PC, Finney JW, Moos RH. Two year posttreatment functioning and coping of patients with substance abuse and posttraumatic stress disorders. *Psychology of Addictive Behaviors*. 1999;13;105-14.

Stabilize Other Disorders - 3

1. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. *JAMA*. 1996;275;761-7.
2. Nunes EV, Levin FR. Treatment of Depression in Patients With Alcohol or Other Drug Dependence: A Meta-analysis. *JAMA*. 2004;291;1887-96.

Models of Treating Comorbid Disorders

1. American Psychiatric Association. *Practice Guidelines for Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine, Opioids*. Washington, DC: American Psychiatric Association; 1995.
2. Harris KM, Edlund MJ. Use of Mental Health Care and Substance Abuse Treatment Among Adults With Co-occurring Disorders *Psychiatr Serv*. 2005;56;954-9.